30 terminated. 30 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 30 | Terminated 30 |
| Phase 2 | 4 | Terminated 4 |
Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML Asciminib, Imatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive | Phase 3 | Terminated | Sarit Assouline | 8 | 2023-11-01 | 2026-05-29 |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 177 | 2021-05-26 | 2025-10-02 |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 252 | 2021-05-24 | 2025-10-21 |
| Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality Optimal medical treatment, usual clinical practice - Chronic Myeloid Leukemia (CML) | Phase 3 | Terminated | University Hospital, Angers | 80 | 2019-12-20 | 2025-03-17 |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 3 | Terminated | Celgene | 38 | 2019-03-27 | 2024-12-12 |
| Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia Dasatinib 100 MG [Sprycel], Nilotinib 150mg oral capsule [Tasigna] - Chronic Myeloid Leukemia - Chronic Phase | Phase 3 | Terminated | Hamad Medical Corporation | 10 | 2017-08-03 | 2019-01-23 |
| The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Anagrelide, Ruxolitinib (JAKAVI®), IFNα/ PegIFNα - Essential Thrombocythemia | Phase 2 / Phase 3 | Terminated | French Innovative Leukemia Organisation | 13 | 2017-01-03 | 2021-06-29 |
| Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. Ruxolitinib, Ruxolitinib Placebo - Myelofibrosis With High Molecular Risk Mutations | Phase 3 | Terminated | Novartis Pharmaceuticals | 49 | 2016-02-03 | 2019-08-16 |
| A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID - Chronic Phase Chronic Myeloid Leukemia | Phase 3 | Terminated | Ariad Pharmaceuticals | 44 | 2015-12-31 | 2021-11-26 |
| Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib Nilotinib - Philadelphia Positive (Ph+) Chronic Myeloid Leukemia | Phase 3 | Terminated | Novartis Pharmaceuticals | 7 | 2015-12-17 | 2019-12-10 |
| Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. Nilotinib - Philidelphia Positive Chronic Myeloid Leukaemia | Phase 3 | Terminated | Novartis Pharmaceuticals | 20 | 2014-07-07 | 2017-10-27 |
| An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years Imatinib, Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Terminated | Prof. Dr. Nikolas von Bubnoff | 14 | 2014-03-01 | 2019-12-02 |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 311 | 2014-02-01 | 2021-11-18 |
| Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 327 | 2013-01-01 | 2020-09-29 |
| Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis ARM A Cyclophosphamide, ARM B Calcineurin inhibitor and methotrexate - Acute Myelogenous Leukemia, Acute Lymphoid Leukemia | Phase 3 | Terminated | Hospital Israelita Albert Einstein | 3 | 2012-12-01 | 2017-03-03 |
| Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) ponatinib, imatinib (Gleevec/ Glivec) - Chronic Myeloid Leukemia | Phase 3 | Terminated | Ariad Pharmaceuticals | 307 | 2012-06-01 | 2014-11-17 |
| Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose), Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI) - Myeloid Malignancies, Acute Myelogenous Leukemia | Phase 3 | Terminated | Hackensack Meridian Health | 53 | 2010-06-16 | 2026-04-03 |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor Donor lymphocyte preparation depleted of host functional alloreactive T-cells - Myeloid Leukemia, Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Kiadis Pharma | 40 | 2009-08-01 | 2021-06-14 |
| Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response Imatinib Mesylate 600 MG Oral Tablet, Imatinib Mesylate 400 MG Oral Tablet, Imatinib Mesylate - Leukemia, Myeloid, Chronic-Phase | Phase 3 | Terminated | Institut Bergonié | 68 | 2009-07-01 | 2020-12-31 |
| Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) Hydroxyurea, Phlebotomy - Polycythemia Vera | Phase 3 | Terminated | Consorzio Mario Negri Sud | 365 | 2008-05-01 | 2012-07-20 |
Showing 20 of 30. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (15) · Leukemia (9) · Leukemia, Myeloid, Chronic-Phase (9) · Primary Myelofibrosis (8) · Myelodysplastic Syndromes (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Bone Marrow Diseases (5) · Leukemia, Myeloid (5) · Graft vs Host Disease (4) · Hematologic Diseases (4) · Leukemia, Myeloid, Acute (4) · Lymphoma (4) · Burkitt Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3)
Hemic and Lymphatic Diseases (30) · Hematologic Diseases (26) · Bone Marrow Diseases (25) · Pathological Conditions, Signs and Symptoms (23) · Neoplasms (22) · Chronic Disease (21) · Disease Attributes (21) · Pathologic Processes (21) · Neoplasms by Histologic Type (20) · Leukemia, Myeloid (17) · Leukemia (13) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7)
Imatinib Mesylate (7) · nilotinib (6) · ruxolitinib (4) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (2) · Dasatinib (2) · Hydroxyurea (2) · Methotrexate (2) · parsaclisib (2) · ponatinib (2) · BID protein, human (1) · Busulfan (1) · Calcineurin Inhibitors (1) · Cyclophosphamide (1) · Cyclosporine (1) · Gemtuzumab (1)
Novartis Pharmaceuticals (5) · Ariad Pharmaceuticals (2) · CTI BioPharma (2) · Incyte Corporation (2) · Alliance for Clinical Trials in Oncology (1) · Baxalta now part of Shire (1) · Bristol-Myers Squibb (1) · Celgene (1) · Consorzio Mario Negri Sud (1) · French Innovative Leukemia Organisation (1) · Hackensack Meridian Health (1) · Hamad Medical Corporation (1) · Hospital Israelita Albert Einstein (1) · Institut Bergonié (1) · Kiadis Pharma (1)
United States (16) · Belgium (9) · France (9) · Germany (9) · Italy (9) · Australia (8) · Canada (8) · United Kingdom (7) · Netherlands (5) · Spain (5) · Austria (4) · Brazil (4) · Czechia (4) · Hungary (4) · Japan (4)
Albert Assad, M.D (1) · Albert Assad, M.D. (1) · Andrea Velardi, MD (1) · Beth Ziemba (1) · Dan DeAngelo, MD (1) · Denis-Claude Roy, MD (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1) · Katy Rezvani, MD PhD (1) · Marcos de Lima, MD (1)
PMID 33275766, PMID 19270260, PMID 22315495, PMID 23216616, PMID 23515925, PMID 24472814, PMID 24859364, PMID 27083332, PMID 34551507, PMID 34699069, PMID 38838026, PMID 39400386, PMID 40227676, PMID 42316774
2008 (1), 2014 (1), 2015 (1), 2018 (1), P30CA069533 (1), U10CA031946 (1)